X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with Divis Laboratories - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs DIVIS LABORATORIES - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. DIVIS LABORATORIES FRESENIUS KABI ONCO./
DIVIS LABORATORIES
 
P/E (TTM) x 22.1 18.5 119.8% View Chart
P/BV x 3.1 4.0 77.9% View Chart
Dividend Yield % 0.0 1.5 -  

Financials

 FRESENIUS KABI ONCO.   DIVIS LABORATORIES
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
DIVIS LABORATORIES
Mar-16
FRESENIUS KABI ONCO./
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1762,484 7.1%   
Low Rs79918 8.6%   
Sales per share (Unadj.) Rs37.7142.3 26.5%  
Earnings per share (Unadj.) Rs5.141.9 12.2%  
Cash flow per share (Unadj.) Rs6.746.3 14.5%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %00.6 0.0%  
Book value per share (Unadj.) Rs42.5161.5 26.3%  
Shares outstanding (eoy) m158.23265.47 59.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.412.0 28.2%   
Avg P/E ratio x25.040.6 61.5%  
P/CF ratio (eoy) x18.936.7 51.6%  
Price / Book Value ratio x3.010.5 28.4%  
Dividend payout %023.9 0.0%   
Avg Mkt Cap Rs m20,135451,525 4.5%   
No. of employees `0001.23.7 31.1%   
Total wages/salary Rs m7033,649 19.3%   
Avg. sales/employee Rs Th5,176.210,184.4 50.8%   
Avg. wages/employee Rs Th610.4984.1 62.0%   
Avg. net profit/employee Rs Th699.62,998.5 23.3%   
INCOME DATA
Net Sales Rs m5,96337,764 15.8%  
Other income Rs m18848 2.1%   
Total revenues Rs m5,98138,612 15.5%   
Gross profit Rs m1,43014,138 10.1%  
Depreciation Rs m2581,182 21.8%   
Interest Rs m-2623 -112.1%   
Profit before tax Rs m1,21613,781 8.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m3422,662 12.9%   
Profit after tax Rs m80611,119 7.2%  
Gross profit margin %24.037.4 64.1%  
Effective tax rate %28.119.3 145.6%   
Net profit margin %13.529.4 45.9%  
BALANCE SHEET DATA
Current assets Rs m5,10230,947 16.5%   
Current liabilities Rs m2,3855,195 45.9%   
Net working cap to sales %45.668.2 66.8%  
Current ratio x2.16.0 35.9%  
Inventory Days Days150117 128.5%  
Debtors Days Days11385 133.1%  
Net fixed assets Rs m5,14817,027 30.2%   
Share capital Rs m158531 29.8%   
"Free" reserves Rs m6,55642,341 15.5%   
Net worth Rs m6,73242,877 15.7%   
Long term debt Rs m9525 20,259.6%   
Total assets Rs m10,38849,684 20.9%  
Interest coverage x-45.8595.0 -7.7%   
Debt to equity ratio x0.10 129,039.7%  
Sales to assets ratio x0.60.8 75.5%   
Return on assets %7.522.4 33.5%  
Return on equity %12.025.9 46.2%  
Return on capital %14.632.2 45.4%  
Exports to sales %74.585.3 87.3%   
Imports to sales %24.822.9 108.1%   
Exports (fob) Rs m4,44132,198 13.8%   
Imports (cif) Rs m1,4778,654 17.1%   
Fx inflow Rs m5,29832,270 16.4%   
Fx outflow Rs m1,7728,775 20.2%   
Net fx Rs m3,52523,496 15.0%   
CASH FLOW
From Operations Rs m1,27410,379 12.3%  
From Investments Rs m-1,204-4,135 29.1%  
From Financial Activity Rs m-196-6,241 3.1%  
Net Cashflow Rs m-1263 -3,827.3%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 11.8 2.5%  
FIIs % 9.6 19.0 50.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 17.2 52.9%  
Shareholders   42,599 31,796 134.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   ELDER PHARMA  FDC LTD.  SUN PHARMA  PLETHICO PHARMA  TTK HEALTHCARE  

Compare FRESENIUS KABI ONCO. With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Amid Fed and ECB Minutes, L&T, Power Grid & IOC Among Other Top Stocks to Watch Out Today(Pre-Open)

On Thursday, Indian share markets oscillated between green and red in a broad range throughout the day and ended the session with marginal gains, with Nifty holding 9,900 mark.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 5-YR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS